Cardiff Oncology (NASDAQ:CRDF) Director Purchases $36,600.00 in Stock

Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Gary Pace acquired 30,000 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The shares were acquired at an average cost of $1.22 per share, for a total transaction of $36,600.00. Following the completion of the transaction, the director directly owned 1,356,376 shares of the company’s stock, valued at $1,654,778.72. The trade was a 2.26% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Cardiff Oncology Stock Performance

NASDAQ CRDF opened at $1.26 on Thursday. Cardiff Oncology, Inc. has a one year low of $1.16 and a one year high of $4.55. The stock has a 50-day moving average of $1.61 and a 200 day moving average of $1.95. The company has a market capitalization of $86.15 million, a price-to-earnings ratio of -1.88 and a beta of 1.36.

Cardiff Oncology (NASDAQ:CRDF) last issued its earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.09 million. Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%. On average, equities analysts predict that Cardiff Oncology, Inc. will post -0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cardiff Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in CRDF. Brooklyn Investment Group bought a new position in shares of Cardiff Oncology in the 3rd quarter worth approximately $26,000. Capital Advisors Wealth Management LLC bought a new stake in Cardiff Oncology during the fourth quarter valued at approximately $30,000. Tamar Securities LLC bought a new stake in Cardiff Oncology during the fourth quarter valued at approximately $32,000. R Squared Ltd bought a new stake in Cardiff Oncology during the fourth quarter valued at approximately $36,000. Finally, Engineers Gate Manager LP purchased a new stake in Cardiff Oncology during the second quarter valued at approximately $43,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CRDF shares. Craig Hallum cut shares of Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a report on Wednesday, June 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a report on Monday, May 18th. Wall Street Zen downgraded shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. HC Wainwright lowered shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Finally, TD Cowen cut Cardiff Oncology from a “buy” rating to a “hold” rating in a report on Monday, June 1st. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.80.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.